ArticleCureus2026
Standardized Saffron Extract Formulation for Low Mood and Subclinical Depressive Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim Low mood with subclinical to mild depressive symptoms represents an early stage of mood disorders with risk of progression to major depression. This study was conducted to evaluate the efficacy and safety of a standardized saffron extract formulation (UO SAF 02, 15 mg) in adults with self-reported low mood and subclinical to mild depressive symptoms. Methods In this randomized, double-blind, placebo-controlled trial, 56 adults aged 18-65 years with self-reported low mood and Beck Depression Inventory (BDI) scores of 10-20 were randomized (1:1) to receive UO SAF 02 or placebo for 56 days. The trial was registered with the Clinical Trials Registry of India (CTRI/2023/11/059603). The primary outcome was the change in total Profile of Mood States (POMS) scores. Secondary outcomes included measures of affective state (Positive and Negative Affect Schedule (PANAS)), depression, anxiety, and stress (Depression Anxiety Stress Scales (DASS-21)), sleep quality (Pittsburgh Sleep Quality Index (PSQI)), and serum cortisol levels. Results Compared with placebo, UO SAF 02 demonstrated significant and consistent improvements in mood-related outcomes, with statistically significant effects observed at Day 28 and maintained through Day 56. POMS scores decreased markedly in the UO SAF 02 group at Day 56 (-48.46 ± 5.39, p < 0.0005) versus the placebo group (-5.67 ± 3.44, p > 0.05). Significant improvements were also observed in affective states, with greater increases in positive affect and reductions in negative affect (p < 0.05), along with reductions in DASS-21 scores (p < 0.001) and improvements in sleep quality (PSQI; p < 0.05). Serum cortisol levels were significantly reduced at both Day 28 and Day 56 (p < 0.05). The intervention was well tolerated, with no serious adverse events reported. Conclusions UO SAF 02 significantly improved psychological and physiological mood-related outcomes in individuals with low mood and subclinical to mild depressive symptoms, supporting its potential as an effective and well-tolerated intervention for mood regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.